Results of a Phase 1 Open-Label, Dose-Escalation Study of Gene Therapy With AAV2-hAQP1 for Grade 2 and 3 Radiation-Induced Late Xerostomia and Parotid Gland Hypofunction
International Journal of Radiation Oncology*Biology*Physics · 2026-10 · 126 (2) · 330-339
DOI: 10.1016/j.ijrobp.2026.04.002 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-10. Verfasst von Michael T Brennan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oral Medicine/Oral and Maxillofacial Surgery, Atrium Health and Wake Forest University, Charlotte, North Carolina. Hauptthemen laut MEDLINE: Xerostomia, Parotid Gland, Genetic Therapy, Radiation Injuries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: Grade 2 and 3 late xerostomia is a chronic, debilitating complication of radiation therapy for head and neck cancers. We assessed the safety and efficacy of AAV2-hAQP1 gene therapy as a treatment for this condition. METHODS AND MATERIALS: Twenty-four participants who reported grade 2 and 3 late xerostomia at screening, ≥5 years after completing their final radiation therapy treatment (≥2 years if human papillomavirus-positive), were enrolled in this open-label, multicenter, dose-escalation study. AAV2-hAQP1 was delivered to the parotid gland(s) via cannulation of Stensen's duct. Twelve participants received AAV2-hAQP1 in 1 gland and 12 in both glands. Participants were followed for 12 months. Safety parameters included adverse events, physical examinations, laboratory tests, and electrocardiograms. Efficacy assessments included the Xerostomia-specific Questionnaire (XQ), MD Anderson Symptom Inventory-Head and Neck Module (MDASI-HN), Global Rate of Change Questionnaire (GRCQ), and measurement of unstimulated whole saliva flow rates (UWSFR). RESULTS: No treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study. When the data from all cohorts were pooled, statistically significant improvements were seen on all patient-reported outcomes by day 30. These were maintained through month 12 with greater improvement in the bilateral cohort. At month 12, the mean percent change from baseline (%CFB) was -39.5% and -42.2% for the XQ Total Score and the MD Anderson Symptom Inventory-Head and Neck Module dry mouth question, respectively, and the mean GRCQ-Symptom Change Score was 3.8. Overall, 16 of 24 (67%) participants reported an improvement of ≥8 points in XQ Total Score, and 19 of 24 (79%) participants reported important improvements in xerostomia symptoms based on the GRCQ. The mean %CFB in UWSFR at month 12 was 112.5%. CONCLUSIONS: Treatment with AAV2-hAQP1 was safe and well-tolerated at all doses and resulted in meaningful improvements in xerostomia symptoms and UWSFR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Oral Medicine/Oral and Maxillofacial Surgery, Atrium Health and Wake Forest University, Charlotte, North Carolina.
- MeiraGTx, New York, New York. Electronic address: Mike.Passineau@meiragtx.com.
- Dental Oncology, Health Sciences North, Sudbury, Ontario, Canada.
- Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts.
- Department of Surgery - Plastic and Reconstructive Surgery, Stanford University, Palo Alto, California.
- MeiraGTx, New York, New York.
Zitieren
APA
Brennan, M. T., Passineau, M. J., Saunders, D., Sroussi, H., Gaudilliere, D., Liu, J., Dubois, N., Fernandez, A., & Zeldin, R. K. (2026). Results of a Phase 1 Open-Label, Dose-Escalation Study of Gene Therapy With AAV2-hAQP1 for Grade 2 and 3 Radiation-Induced Late Xerostomia and Parotid Gland Hypofunction. International Journal of Radiation Oncology*Biology*Physics, 126(2), 330-339. https://doi.org/10.1016/j.ijrobp.2026.04.002
Vancouver
Brennan MT, Passineau MJ, Saunders D, Sroussi H, Gaudilliere D, Liu J, et al. Results of a Phase 1 Open-Label, Dose-Escalation Study of Gene Therapy With AAV2-hAQP1 for Grade 2 and 3 Radiation-Induced Late Xerostomia and Parotid Gland Hypofunction. International Journal of Radiation Oncology*Biology*Physics. 2026;126(2):330-339. doi:10.1016/j.ijrobp.2026.04.002
BibTeX
@article{Brennan2026,
author = {Brennan, Michael T and Passineau, Michael J and Saunders, Deborah and Sroussi, Herve and Gaudilliere, Dyani and Liu, Jun and Dubois, Nathalie and Fernandez, Arthur and Zeldin, Robert K},
title = {Results of a Phase 1 Open-Label, Dose-Escalation Study of Gene Therapy With AAV2-hAQP1 for Grade 2 and 3 Radiation-Induced Late Xerostomia and Parotid Gland Hypofunction},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {2},
pages = {330--339},
doi = {10.1016/j.ijrobp.2026.04.002}
}
EUVIMED